期刊文献+

利培酮及奥氮平在难治性精神分裂症治疗中的临床药学分析 被引量:8

Clinical pharmaceutical analysis on risperidone and olanzapine in the treatment of refractory schizophrenia
下载PDF
导出
摘要 目的 探讨在难治性精神分裂症治疗中运用利培酮及奥氮平的效果及临床药学分析.方法 采用计算机随机抽样分组的方式将2017年1月~2019年2月广东省茂名市第三人民医院精神科难治性精神分裂症60例患者分为利培酮组(n=30,利培酮治疗)与奥氮平组(n=30,奥氮平治疗),分析效果.结果 奥氮平组总有效率及治疗后HVLT-R、WMS评分与利培酮组比较,差异无统计学意义(P>0.05).奥氮平组治疗后WCST评分与利培酮组比较更高,差异有统计学意义(P<0.05).奥氮平组中体重增加、嗜睡发生率与利培酮组比较更高,奥氮平组中锥体外系反应、头晕头疼发生率与利培酮组比较更低,差异有统计学意义(P<0.05).结论 对难治性精神分裂症患者运用利培酮与奥氮平治疗疗效相当,但奥氮平对执行能力改善效果更好,用药中易出现体重增加、嗜睡. Objective To explore the efficacy of risperidone and olanzapine in the treatment of refractory schizophrenia and clinical pharmaceutical analysis.Methods Sixty patients with refractory schizophrenia admitted to Maoming Third People’s Hospital of Guangdong from January 2017 to February 2019 were selected using the random sampling and grouping with computer and divided into two groups:risperidone group(n=30,treatment with risperidone)and olanzapine group(n=30,treatment with olanzapine)to analyze efficacyrespectively.Results By comparing the overall response rate,post-treatment HVLT-R and WMS scores between olanzapine group and risperidone group,the differenceswere not statistically significant(P>0.05).In inter-group comparison,posttreatment WCST score of olanzapine group was higher than that of risperidone group,the differencewas statistically significant(P<0.05).The weight gain and incidence of drowsiness of olanzapine group were higher than those of risperidone group by inter-group comparison,while the incidences of extrapyramidal reaction,dizziness and headache of olanzapine group were higher than those of risperidone group by inter-group comparison,the differences were statistically significant(P<0.05).Conclusion Administration of risperidone and olanzapine in patients with refractory schizophrenia has comparable efficacy,but the improvement of executive capability induced by olanzapine issuperior torisperidone.However it’s easy to develop weight gain and drowsiness during administration.
作者 黄春燕 HUANG Chunyan(Pharmacy Department of Maoming Third People’s Hospital,Guangdong,Maoming 525000,China)
出处 《中国医药科学》 2020年第10期57-59,91,共4页 China Medicine And Pharmacy
关键词 难治性精神分裂症 利培酮 奥氮平 药学 认知功能 Refractory schizophrenia Risperidone Olanzapine Pharmacy Cognitive function
  • 相关文献

参考文献16

二级参考文献130

  • 1黄雄,朱海兵,麦桂英.奥氮平和利培酮治疗首发儿童青少年精神分裂症疗效对比[J].广东医学,2006,27(2):270-272. 被引量:6
  • 2陈庆华,陈刚,唐海芸.利培酮长效注射剂的药动学特征和临床应用[J].中国新药杂志,2006,15(15):1235-1238. 被引量:8
  • 3杨甫德,陈斌,孙毅,赵祖安,马征,李娟,谭云龙.国产利培酮治疗精神分裂症的临床研究[J].北京医学,2006,28(10):618-621. 被引量:2
  • 4Kahn RS, Keefe RS. Schizophrenia is a cognitive illness : time for a change in tbcus[ Jl. JAMA Psychiatry, 2013,70(10) : 1107- 1112. 被引量:1
  • 5Bowie CR, Reichenberg A, Patterson TL, et al. Determinants of zal-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms [J]. Am J Psychiatry, 2006,163(3) :418-425. 被引量:1
  • 6Green MF, Nuechterlein KH, Kern RS, et al. Functional co- primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study[ J]. Am J Psyehiatry, 2008,165 ( 2 ) : 221-228. 被引量:1
  • 7Kern RS, Nuechterlein KH, Green MF, et al. The MATR1CS Consensus Cognitive Battery, part 2: co-norming and standardization [ J ]. Am J Psychiatry, 2008,165 ( 2 ) : 214-220. 被引量:1
  • 8Nuechterlein KH, Green MF, Kern RS, et al. The MATR1CS Consensus Cognitive Battery, part 1: test selection, reliability, and validity [ J ]. Am J Psychiat3,, 2008, 165 ( 2 ) : 203-213. 被引量:1
  • 9Fatouros-Bergman H, Cervenka S, Flyckt L, et al. Meta-analysis of cognitive performance in drug-nf've patients with schizophrenia [J]. SchizophrRes, 2014,158(1-3) :156-162. 被引量:1
  • 10刘娜,熊祥玉,应颖,等.首发精神分裂症患者治疗早期神经认知功能改变的对照研究[C]//中国神经科学学会精神病学基础与临床分会学术会议,2012. 被引量:1

共引文献395

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部